• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.

作者信息

Price P, Hogan S J, Horwich A

机构信息

Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.

出版信息

Eur J Cancer. 1990 Apr;26(4):450-3. doi: 10.1016/0277-5379(90)90014-k.

DOI:10.1016/0277-5379(90)90014-k
PMID:1694086
Abstract

Changes in serum tumour marker levels in non-seminomatous germ cell testicular tumours (NSGCTT) are used to monitor tumour growth and response to treatment. A novel method of calculating the actual tumour marker production (TMP) per day is reported; estimation of the rate of change of TMP is a measure of the tumour growth or regression rate. TMP is calculated mathematically from the rate of increase in serum marker level and its natural half life. TMP is assumed to be proportional to the number of marker producing cells in the tumour. TMP was calculated over the time between orchidectomy and the start of chemotherapy. The rate of increase in TMP with time is expressed as the marker production doubling time (MPDT) and is a measure of the growth rate. In a group of 51 patients with metastatic NSGCTT, TMP varied from 0.012 to 5985 iu/l/day (AFP) and 0.08-5404 iu/l/day (HCG). MPDT varied from 0.5 to greater than 80 days (45 cases) for AFP + ve patients and from 1.8 to greater than 80 days (34 cases) for HCG + ve patients; greater than 80% of cases had a MPDT less than or equal to 32 days. In 45/51 (88%) patients, there was no discrepancy in MPDT between markers. The use of changes in serum marker level to follow tumour progression and regression is simple, but the calculation of actual TMP provides clearer information about the change in number of marker producing cells and can be used as non-invasive method for measuring the tumour growth rate of metastatic disease and response to treatment.

摘要

相似文献

1
The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
Eur J Cancer. 1990 Apr;26(4):450-3. doi: 10.1016/0277-5379(90)90014-k.
2
The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.通过标志物产生倍增时间测量的转移性非精原细胞性睾丸生殖细胞肿瘤的生长速率——II. 化疗患者的预后意义
Eur J Cancer. 1990 Apr;26(4):453-7. doi: 10.1016/0277-5379(90)90015-l.
3
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.基于预后不良生殖细胞肿瘤肿瘤标志物下降的个体化化疗(GETUG 13):一项3期多中心随机试验
Lancet Oncol. 2014 Dec;15(13):1442-1450. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.
4
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.化疗开始时的肿瘤标志物浓度比标志物半衰期更能有力地预测治疗失败:一项针对播散性非精原细胞瘤性睾丸癌患者的研究。
Br J Cancer. 1997;75(3):432-5. doi: 10.1038/bjc.1997.71.
5
Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Acta Oncol. 1999;38(4):505-9. doi: 10.1080/028418699432059.
6
[Tumor marker diagnosis in non-seminomatous testicular tumors using human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP)].使用人绒毛膜促性腺激素(HCG)和甲胎蛋白(AFP)对非精原细胞瘤性睾丸肿瘤进行肿瘤标志物诊断
Z Urol Nephrol. 1985 Feb;78(2):77-86.
7
Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.肿瘤标志物分析在预后不良的转移性非精原细胞性生殖细胞肿瘤中的预后意义
Eur J Cancer. 1993;29A(7):961-5. doi: 10.1016/s0959-8049(05)80202-3.
8
Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.血清乳酸脱氢酶同工酶1和肿瘤体积是转移性睾丸生殖细胞肿瘤治疗反应的指标和预后的预测因素。
Eur J Cancer. 1992;28(2-3):410-5. doi: 10.1016/s0959-8049(05)80064-4.
9
Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
Oncodev Biol Med. 1983;4(4):289-308.
10
Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.非精原细胞性生殖细胞肿瘤患者血清肿瘤标志物监测的频率
Br J Cancer. 1990 Jun;61(6):916-8. doi: 10.1038/bjc.1990.205.

引用本文的文献

1
A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).一项针对预后不良生殖细胞肿瘤的强化诱导化疗(CBOP/BEP)与标准BEP的随机2期试验(MRC TE23、CRUK 05/014、ISRCTN 53643604)。
Eur Urol. 2015 Mar;67(3):534-43. doi: 10.1016/j.eururo.2014.06.034. Epub 2014 Jul 4.